[go: up one dir, main page]

NO20073719L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO20073719L
NO20073719L NO20073719A NO20073719A NO20073719L NO 20073719 L NO20073719 L NO 20073719L NO 20073719 A NO20073719 A NO 20073719A NO 20073719 A NO20073719 A NO 20073719A NO 20073719 L NO20073719 L NO 20073719L
Authority
NO
Norway
Prior art keywords
chemical compounds
relates
useful
cancer
chemical connections
Prior art date
Application number
NO20073719A
Other languages
English (en)
Norwegian (no)
Inventor
Paul Dermot Lyne
Brian Aquila
Timothy Pontz
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073719L publication Critical patent/NO20073719L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20073719A 2005-01-25 2007-07-18 Kjemiske forbindelser NO20073719L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64682005P 2005-01-25 2005-01-25
PCT/GB2006/000223 WO2006079791A1 (fr) 2005-01-25 2006-01-24 Composes chimiques

Publications (1)

Publication Number Publication Date
NO20073719L true NO20073719L (no) 2007-08-22

Family

ID=36588681

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073719A NO20073719L (no) 2005-01-25 2007-07-18 Kjemiske forbindelser

Country Status (13)

Country Link
US (1) US20080146570A1 (fr)
EP (1) EP1924573A1 (fr)
JP (1) JP2008528473A (fr)
KR (1) KR20070107061A (fr)
CN (1) CN101146789A (fr)
AU (1) AU2006208834A1 (fr)
BR (1) BRPI0606930A2 (fr)
CA (1) CA2594708A1 (fr)
IL (1) IL184673A0 (fr)
MX (1) MX2007008924A (fr)
NO (1) NO20073719L (fr)
WO (1) WO2006079791A1 (fr)
ZA (1) ZA200706497B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513329A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体
KR20100117686A (ko) * 2008-02-29 2010-11-03 어레이 바이오파마 인크. 피라졸[3,4-ｂ]피리딘 ｒａｆ 저해물질
TW200940540A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
CA2716949A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Derives de n-(6-aminopyridin-3-yl)-3-(sulfonamido) benzamide comme inhibiteurs de b-raf pour le traitement du cancer
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
ES2417355T3 (es) * 2009-05-19 2013-08-07 Dow Agrosciences Llc Compuestos y métodos para el control de hongos
NZ622505A (en) 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CN102548987B (zh) * 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 作为激酶抑制剂的氟取代化合物及其使用方法
CA2793835C (fr) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Procedes et compositions pour des troubles relatifs
EP2701507A1 (fr) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Utilisation de composés hétérocycliques comme inhibiteurs de b-raf dans le traitement du cancer
PT2704721T (pt) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
DK2800743T3 (en) 2012-01-06 2018-06-14 Agios Pharmaceuticals Inc THERAPEUTIC ACTIVE RELATIONS AND PROCEDURES FOR USE THEREOF
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
MX365747B (es) 2012-10-15 2019-06-12 Agios Pharmaceuticals Inc Compuestos derivados de diarilurea de sulfonamida de arilo y sus usos.
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
CN105492435B (zh) 2013-07-11 2018-06-29 安吉奥斯医药品有限公司 作为idh2突变体抑制剂的化合物
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
EP4431502A4 (fr) * 2021-11-12 2025-11-05 Unimatec Co Ltd Composés de pyrimidine contenant du fluor, agent de lutte contre les champignons nuisibles et procédé de production de composés de pyrimidine contenant du fluor
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047690A1 (fr) * 2000-12-12 2002-06-20 Cytovia, Inc. 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf

Also Published As

Publication number Publication date
AU2006208834A1 (en) 2006-08-03
JP2008528473A (ja) 2008-07-31
MX2007008924A (es) 2007-08-21
CA2594708A1 (fr) 2006-08-03
CN101146789A (zh) 2008-03-19
US20080146570A1 (en) 2008-06-19
BRPI0606930A2 (pt) 2009-12-01
KR20070107061A (ko) 2007-11-06
ZA200706497B (en) 2008-08-27
IL184673A0 (en) 2007-12-03
WO2006079791A1 (fr) 2006-08-03
EP1924573A1 (fr) 2008-05-28

Similar Documents

Publication Publication Date Title
NO20073719L (no) Kjemiske forbindelser
NO20082709L (no) Kjemiske forbindelser
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20091683L (no) Kjemiske forbindelser
NO20070566L (no) Azin-karboksamider som antikreftmiddel
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
TW200635899A (en) Chemical compounds
WO2007113558A8 (fr) Composés chimiques
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20082690L (no) Kjemiske forbindelser
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
TW200736234A (en) Chemical compounds
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20061743L (no) Kinazolinderivater
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
NO20074856L (no) Transkarotenoide, deres syntese, formulering og anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application